Rare NRG1 Fusion Market is Expected to Showcase a Significant Growth by 2032, Predicts DelveInsight | Key Companies – Merus, Hummingbird Bioscience, Elevation Oncology, Rain Therapeutics, and Others

June 30 16:06 2022
Rare NRG1 Fusion Market is Expected to Showcase a Significant Growth by 2032, Predicts DelveInsight | Key Companies - Merus, Hummingbird Bioscience, Elevation Oncology, Rain Therapeutics, and Others
Delveinsight Business Research LLP
DelveInsight’s “Rare NRG1 Fusion Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Rare NRG1 Fusion Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Rare NRG1 Fusion market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Rare NRG1 Fusion Market

Rare NRG1 Fusion: An Overview

The Neuregulin-1 (NRG1) gene encodes for the neuregulin 1, a growth factor belonging to the complex family of proteins also called heregulins. These proteins are structurally related to the stimulation of ERBB receptor tyrosine kinase activity and EGF signals. Specifically, the NRG1-receptor binding induces the phosphorylation of the intrinsic kinase domains of ERBB3 and stimulates its dimerization with ERBB2 receptor and the activation of the downstream PI3K-AKT and MAPK pathways.

NRG1 fusions are a rare but powerful oncogene driver that makes cancer particularly aggressive and deadly when it is present. Therefore, they have emerged as a potential therapeutic target across multiple tumor types.

Rare NRG1 Fusion Market Key Facts

According to a study conducted by Russo et al. (2019) titled “NTRK and NRG1 gene Fusions in advanced non-small cell lung cancer (NSCLC)”, the reported incidence of NRG1 Fusions is of approximately 0.2–0.5% in unselected NSCLCs. To date, 18 different fusion partners for NRG1 have been reported in NSCLCs and the CD74-NRG1 fusion variant is the most common in NSCLCs.

Rare NRG1 Fusion Market

Rare NRG1 Fusion market size is expected to increase in the coming years owing to the rise in number of incident cases in the 7MM

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Rare NRG1 Fusion market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Rare NRG1 Fusion market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.

Rare NRG1 Fusion Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.

Rare NRG1 Fusion Epidemiology Segmentation

  • Incident cases of specific cancer types (lung, pancreatic and others)

  • Diagnosed and Treatable Cases of Rare NRG1 Fusion in the respective cancer types

  • Incident cases of Rare NRG1 Fusion in the respective cancer types

Rare NRG1 Fusion Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Rare NRG1 Fusion market or expected to get launched during the study period. The analysis covers Rare NRG1 Fusion market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Rare NRG1 Fusion Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report – https://www.delveinsight.com/sample-request/rare-nrg1-fusion-market

Rare NRG1 Fusion Therapeutics Analysis

The Rare NRG1 Fusion therapeutics pipeline is quite weak as it possesses very few potential key players. However, the dynamics of the market is anticipated to change in the coming years owing to the improvement in the research and development activities so that market will comprise of efficient treatment options. The launch of emerging therapies is expected in the near future.

Some of the key companies in the Rare NRG1 Fusion Market:

  • Merus 

  • Hummingbird Bioscience

  • Elevation Oncology

  • Rain Therapeutics

And many others.

Rare NRG1 Fusion Therapies covered in the report include:

  • HMBD-001

  • Seribantumab

  • Tarloxotinib

  • Zenocutuzumab

And many more.

Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/rare-nrg1-fusion-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Rare NRG1 Fusion Competitive Intelligence Analysis

4. Rare NRG1 Fusion Market Overview at a Glance

5. Rare NRG1 Fusion Disease Background and Overview

6. Rare NRG1 Fusion Patient Journey

7. Rare NRG1 Fusion Epidemiology and Patient Population

8. Rare NRG1 Fusion Treatment Algorithm, Current Treatment, and Medical Practices

9. Rare NRG1 Fusion Unmet Needs

10. Key Endpoints of Rare NRG1 Fusion Treatment

11. Rare NRG1 Fusion Marketed Products

12. Rare NRG1 Fusion Emerging Therapies

13. Rare NRG1 Fusion Seven Major Market Analysis

14. Attribute Analysis

15. Rare NRG1 Fusion Market Outlook (7 major markets)

16. Rare NRG1 Fusion Access and Reimbursement Overview

17. KOL Views on the Rare NRG1 Fusion Market.

18. Rare NRG1 Fusion Market Drivers

19. Rare NRG1 Fusion Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report – https://www.delveinsight.com/sample-request/rare-nrg1-fusion-market

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

 

Other Trending Healthcare Reports by DelveInsight

Hypercoagulability Market
“Hypercoagulability Market” research report delivers an in-depth understanding of the historical and forecasted epidemiology, Hypercoagulability market size, share, and trends in the 7MM as well as the key insights into the potential emerging therapies and key pharma companies operating in the therapeutics market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/